The study also suggests that in GBM, patients with (wild-type) TP53 non-mutated have a statistically significant increase in EGFR upregulation compared to those with TP53-mutant, although the impact of the cancer stage on this association remains unclear. This evidence concerns the gene EGFR and glioblastoma.